Cintas Corporation has been named one of Newsweek’s Most Trustworthy Companies in America for 2026, marking a consistent recognition of trust from customers, investors, and employee-partners. Cintas President and CEO, Todd Schneider, emphasized that trust is fundamental to the company's operations and relationships. This award follows a previous recognition as one of the World’s Most Trustworthy Companies in 2025.

Robbins LLP has issued a stockholder alert, reminding investors of a class action lawsuit filed against Zoetis Inc. The lawsuit alleges that Zoetis misled investors regarding the performance of its flagship products, Librela, Simparica Trio, Apoquel, and Cytopoint, due to weakening prescription growth, market share loss, and safety concerns. This resulted in a significant drop in Zoetis's stock price, and shareholders who purchased securities between January 14, 2025, and May 6, 2026, may be eligible to participate as lead plaintiffs.

Newton Golf Company, Inc. (NASDAQ: NWTG) will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026, where management will discuss the company's expansion, product evaluations, and provide a Q&A session. The company reported record net sales of $8.1 million in 2025, a 136% growth over 2024, and recently appointed Gregg Hemphill to its board of directors. Newton Golf focuses on physics-driven engineering for its golf equipment, including Newton Motion shafts and Gravity putters.

NeoVolta Inc. has announced the pricing of a public offering of 12,195,122 shares of common stock at $2.05 per share, aiming to raise approximately $25.0 million. The energy storage solutions company has also granted the underwriter a 30-day option to purchase additional shares. Despite the stock currently trading below the offering price, InvestingPro analysis suggests it is undervalued, noting that the company holds more cash than debt and anticipates sales growth.

Osisko Development Corp. (NYSE: ODV, TSXV: ODV) announced its intent to complete the fourth of five deferred payments for the Tintic Project acquisition. This payment of US$2,500,000 will be made entirely in Common Shares, totaling 871,683 shares at a deemed price of C$3.9613 per share, subject to TSX Venture Exchange approval. The Tintic Project, located in Utah, USA, was acquired in May 2022.

UBS upgraded Ecolab Inc. (NYSE: ECL) to Buy from Neutral, raising its price target to $325 from $293, anticipating accelerating pricing in the latter half of 2026 to offset raw material costs. The firm expects the company's "OneECL" initiatives and increasing exposure to high-tech industries to boost market share and annual volume growth. This upgrade comes despite a recent slight reduction in price recommendation by Jefferies, which still maintains a Buy rating for ECL.

A rumor circulated that Dr Pepper Creamy Coconut, a limited-edition summer flavor, would become a permanent offering. However, a Sporked journalist investigated and confirmed with multiple sources at Keurig Dr Pepper that this is not true and the flavor will still be discontinued at the end of July. The rumor likely originated from a misunderstanding at a trade show focused on foodservice, where representatives were not qualified to speak on retail product plans.

Jefferies has upgraded C.H. Robinson (CHRW) to Buy and raised its price target, citing the company's technology and productivity transformation. The firm believes the current share levels offer a compelling entry point, especially given the regulatory environment that favors larger, scaled brokers after the Montgomery versus Caribe Transport Supreme Court ruling. JPMorgan also added CHRW to its Analyst Focus List, highlighting Robinson's scale advantages in this new regulatory landscape.

Vertex Pharmaceuticals' drug Journavx, despite being the first novel pain medicine approved by the FDA in decades, has not fully met initial sales projections or closed the gap for non-addictive pain relief. Targeting a specific sodium channel, Journavx is often used as an add-on rather than a substitute for opioids, prompting other companies like Tris Pharma to develop alternative, less addictive pain treatments. The industry continues its search for effective opioid alternatives, with many focusing on ion channel drugs.

Billionaire Tilman Fertitta's Fertitta Entertainment is acquiring Caesars Entertainment for $5.7 billion, taking on nearly $12 billion in debt, to create a massive entertainment empire. The all-cash deal will combine Fertitta's Landry's restaurants and Golden Nugget properties with Caesars' 52 casinos, including Harrah's and Circus Circus. Caesars investors will receive a 49% premium on their shares, with the company able to seek competing bids until July 11.